Abstract Presentations Highlight Durable Pain
Relief and Improved Quality of Life for Patients Receiving 10 kHz
Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy and
Non-Surgical Back Pain
Symposium on the Future of SCS and How AI
Technology Can Improve Outcomes with HFX iQ™
REDWOOD
CITY, Calif., July 13,
2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company that is delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced that 24-month data from the SENZA Painful Diabetic
Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT
to evaluate spinal cord stimulation (SCS) to treat PDN, and
24-month data from the SENZA Non-Surgical Refractory Back Pain
(NSRBP) RCT will be presented at the American Society of Pain &
Neuroscience (ASPN) Fifth Annual Conference to be held July 13-16, 2023 in Miami Beach, FL.
Nevro will also feature its HFX™ platform of SCS solutions in
Exhibit Booth #223 and in a lunch symposium featuring Drs.
Kasra Amirdelfan, Alexander Escobar, Usman
Latif and Peter
Pryzbylkowski. During the lunch symposium, presenters will
highlight HFX iQ™, the first and only AI-based SCS system that
learns from patients. It was developed to address the variability
in pain from patient to patient and to help patients optimize and
maintain long-term pain relief and improved quality of life.
Details for the abstract and lunch symposium presentations are
below:
24-Month Durability of Pain Relief, Function, Quality of Life
and Safety Outcomes for Non-Surgical Refractory Back Pain Patients
with 10 kHz Spinal Cord
- Presenter: Leonardo Kapural, MD, PhD
- Date: Friday, July 14, 2023
- Time: 1:48-1:55 PM ET
- Location: Fontaine/Fleur de Lis
10 kHz SCS Provides Significant, Durable Pain Relief and
Improved Lower Extremity Protective Sensation for Patients with
Painful Diabetic Neuropathy
- Presenter: Erika Petersen,
MD
- Date: Saturday, July 15,
2023
- Time: 9:01-9:08 AM ET
- Location: Fontaine Ballroom
HFX iQ Lunch Symposium
- Presenters: Kasra Amirdelfan,
MD, Alexander Escobar, MD,
Usman Latif, MD, MBA, and
Peter Pryzbylkowski, MD
- Date: Saturday, July 15,
2023
- Time: 12:00-1:00 PM ET
- Location: Splash 11/12
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes a Senza SCS system and support
services for the treatment of chronic pain of the trunk and limb
and painful diabetic neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS
systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's
unique support services provide every patient with an HFX Coach™
throughout their pain relief journey and every physician with HFX
Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us
on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | julie.dewey@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-announces-presentations-at-american-society-of-pain--neuroscience-fifth-annual-conference-301870952.html
SOURCE Nevro Corp.